Switch theme
Sign up to access all valuation multiples
Supriya Lifescience Ltd is a manufacturer of Active pharmaceutical Ingredients. It is focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.
2008
448
LTM Revenue $85.6M
LTM EBITDA $30.2M
$673M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Supriya Lifescience has a last 12-month revenue (LTM) of $85.6M and a last 12-month EBITDA of $30.2M.
In the most recent fiscal year, Supriya Lifescience achieved revenue of $81.6M and an EBITDA of $31.7M.
Supriya Lifescience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Supriya Lifescience valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $85.6M | XXX | $81.6M | XXX | XXX | XXX |
| Gross Profit | $85.6M | XXX | $56.8M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $30.2M | XXX | $31.7M | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 39% | XXX | XXX | XXX |
| EBIT | n/a | XXX | $28.1M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | 35% | XXX | XXX | XXX |
| Net Profit | $20.7M | XXX | $22.0M | XXX | XXX | XXX |
| Net Margin | 24% | XXX | 27% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Supriya Lifescience's stock price is INR 724 (or $8).
Supriya Lifescience has current market cap of INR 58.2B (or $682M), and EV of INR 57.5B (or $673M).
See Supriya Lifescience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $673M | $682M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Supriya Lifescience has market cap of $682M and EV of $673M.
Supriya Lifescience's trades at 8.7x EV/Revenue multiple, and 23.1x EV/EBITDA.
Equity research analysts estimate Supriya Lifescience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Supriya Lifescience has a P/E ratio of 32.9x.
See valuation multiples for Supriya Lifescience and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $682M | XXX | $682M | XXX | XXX | XXX |
| EV (current) | $673M | XXX | $673M | XXX | XXX | XXX |
| EV/Revenue | 7.9x | XXX | 8.7x | XXX | XXX | XXX |
| EV/EBITDA | 22.3x | XXX | 23.1x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 26.2x | XXX | XXX | XXX |
| EV/Gross Profit | 7.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 32.9x | XXX | 34.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -903.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSupriya Lifescience's last 12 month revenue growth is 20%
Supriya Lifescience's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Supriya Lifescience's rule of 40 is 58% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Supriya Lifescience's rule of X is 85% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Supriya Lifescience and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 58% | XXX | 58% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 85% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Race Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascentage Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Actuate Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Black Diamond Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Supriya Lifescience acquired XXX companies to date.
Last acquisition by Supriya Lifescience was XXXXXXXX, XXXXX XXXXX XXXXXX . Supriya Lifescience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Supriya Lifescience founded? | Supriya Lifescience was founded in 2008. |
| Where is Supriya Lifescience headquartered? | Supriya Lifescience is headquartered in India. |
| How many employees does Supriya Lifescience have? | As of today, Supriya Lifescience has 448 employees. |
| Is Supriya Lifescience publicy listed? | Yes, Supriya Lifescience is a public company listed on BOM. |
| What is the stock symbol of Supriya Lifescience? | Supriya Lifescience trades under 543434 ticker. |
| When did Supriya Lifescience go public? | Supriya Lifescience went public in 2021. |
| Who are competitors of Supriya Lifescience? | Similar companies to Supriya Lifescience include e.g. Race Oncology, Ascentage Pharma Group, ST Pharm, Actuate Therapeutics. |
| What is the current market cap of Supriya Lifescience? | Supriya Lifescience's current market cap is $682M |
| What is the current revenue of Supriya Lifescience? | Supriya Lifescience's last 12 months revenue is $85.6M. |
| What is the current revenue growth of Supriya Lifescience? | Supriya Lifescience revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Supriya Lifescience? | Current revenue multiple of Supriya Lifescience is 7.9x. |
| Is Supriya Lifescience profitable? | Yes, Supriya Lifescience is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Supriya Lifescience? | Supriya Lifescience's last 12 months EBITDA is $30.2M. |
| What is Supriya Lifescience's EBITDA margin? | Supriya Lifescience's last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of Supriya Lifescience? | Current EBITDA multiple of Supriya Lifescience is 22.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
